Tokyo Tape
Sign in
← Chiome Bioscience

Annual report

4583.TEDINET S100XUJT
Period2025-01-01 → 2025-12-31
Filed2026-03-27
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 76
MetricValuePeriodScopeSource row
Revenue¥593m2025-01-01 → 2025-12-31StandaloneNet sales
Revenue¥781m2024-01-01 → 2024-12-31StandaloneNet sales
Revenue¥682m2023-01-01 → 2023-12-31vStandaloneNet sales (5-year summary)
Revenue¥631m2022-01-01 → 2022-12-31vStandaloneNet sales (5-year summary)
Revenue¥713m2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Operating income−¥980m2025-01-01 → 2025-12-31StandaloneOperating income
Operating income−¥1.0bn2024-01-01 → 2024-12-31StandaloneOperating income
Ordinary income−¥989m2025-01-01 → 2025-12-31StandaloneOrdinary income
Ordinary income−¥1.0bn2024-01-01 → 2024-12-31StandaloneOrdinary income
Ordinary income−¥1.2bn2023-01-01 → 2023-12-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.2bn2022-01-01 → 2022-12-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.3bn2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥980m2025-01-01 → 2025-12-31StandaloneIncome before income taxes
Profit before tax−¥1.0bn2024-01-01 → 2024-12-31StandaloneIncome before income taxes
Net income−¥983m2025-01-01 → 2025-12-31StandaloneProfit loss
Net income−¥1.0bn2024-01-01 → 2024-12-31StandaloneProfit loss
Net income−¥1.2bn2023-01-01 → 2023-12-31vStandaloneNet income loss (5-year summary)
Net income−¥1.2bn2022-01-01 → 2022-12-31vStandaloneNet income loss (5-year summary)
Net income−¥1.5bn2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Total assets¥1.7bnat 2025-12-31StandaloneAssets
Total assets¥2.5bnat 2024-12-31StandaloneAssets
Total assets¥1.8bnat 2023-12-31vStandaloneTotal assets (5-year summary)
Total assets¥2.2bnat 2022-12-31vStandaloneTotal assets (5-year summary)
Total assets¥2.3bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥605mat 2025-12-31StandaloneLiabilities
Total liabilities¥549mat 2024-12-31StandaloneLiabilities
Net assets / equity¥1.1bnat 2025-12-31StandaloneNet assets
Net assets / equity¥1.9bnat 2024-12-31StandaloneNet assets
Net assets / equity¥1.2bnat 2023-12-31vStandaloneNet assets
Net assets / equity¥1.8bnat 2022-12-31vStandaloneNet assets (5-year summary)
Net assets / equity¥1.9bnat 2021-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥1.2bnat 2025-12-31StandaloneCash and deposits
Cash and deposits¥2.1bnat 2024-12-31StandaloneCash and deposits
Cash & equivalents¥1.2bnat 2025-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.1bnat 2024-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.3bnat 2023-12-31vStandaloneCash and cash equivalents
Cash & equivalents¥1.7bnat 2022-12-31vStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥1.8bnat 2021-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥936m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.0bn2024-01-01 → 2024-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.1bn2023-01-01 → 2023-12-31vStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.2bn2022-01-01 → 2022-12-31vStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.1bn2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥55m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥173,0002023-01-01 → 2023-12-31vStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥35m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥133m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.7bn2024-01-01 → 2024-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥667m2023-01-01 → 2023-12-31vStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.1bn2022-01-01 → 2022-12-31vStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥271m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-14.472025-01-01 → 2025-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-17.542024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-24.622023-01-01 → 2023-12-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-28.262022-01-01 → 2022-12-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.742021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥16.18at 2025-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥28.53at 2024-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥21.66at 2023-12-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥36.7at 2022-12-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥45.55at 2021-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio64.1%at 2025-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio77.4%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio65.1%at 2023-12-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio80.2%at 2022-12-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio79.4%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued68,453,800at 2025-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued66,969,000at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued52,640,200at 2023-12-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued48,423,500at 2022-12-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued40,781,500at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees49at 2025-12-31StandaloneNumber of employees
Employees47at 2024-12-31StandaloneNumber of employees
Employees51at 2023-12-31vStandaloneNumber of employees
Employees49at 2022-12-31vStandaloneNumber of employees
Employees49at 2021-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 22
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2025-01-01 → 2025-12-31−¥559m
Drug Discovery And Developmentreportable segmentsegment profit2025-01-01 → 2025-12-31−¥777m
Drug Discovery Supportreportable segmentdepreciation2025-01-01 → 2025-12-31¥4m
Drug Discovery Supportreportable segmentrevenue2025-01-01 → 2025-12-31¥593m
Drug Discovery Supportreportable segmentrevenue external2025-01-01 → 2025-12-31¥593m
Drug Discovery Supportreportable segmentsegment profit2025-01-01 → 2025-12-31¥356m
—segment totalemployeesat 2025-12-3139 pure
Total Of Reportable Segments And Otherssegment totaldepreciation2025-01-01 → 2025-12-31¥4m
Total Of Reportable Segments And Otherssegment totalrevenue2025-01-01 → 2025-12-31¥593m
Total Of Reportable Segments And Otherssegment totalrevenue external2025-01-01 → 2025-12-31¥593m
Total Of Reportable Segments And Otherssegment totalsegment profit2025-01-01 → 2025-12-31−¥421m
Reconciling Itemsreconcilingdepreciation2024-01-01 → 2024-12-31¥1m
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-12-31−¥527m
Drug Discovery And Developmentreportable segmentrevenue2024-01-01 → 2024-12-31¥203m
Drug Discovery And Developmentreportable segmentrevenue external2024-01-01 → 2024-12-31¥203m
Drug Discovery And Developmentreportable segmentsegment profit2024-01-01 → 2024-12-31−¥814m
Drug Discovery Supportreportable segmentrevenue2024-01-01 → 2024-12-31¥578m
Drug Discovery Supportreportable segmentrevenue external2024-01-01 → 2024-12-31¥578m
Drug Discovery Supportreportable segmentsegment profit2024-01-01 → 2024-12-31¥310m
Total Of Reportable Segments And Otherssegment totalrevenue2024-01-01 → 2024-12-31¥781m
Total Of Reportable Segments And Otherssegment totalrevenue external2024-01-01 → 2024-12-31¥781m
Total Of Reportable Segments And Otherssegment totalsegment profit2024-01-01 → 2024-12-31−¥504m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 832
ItemContextValueUnit
Net cash provided by used in operating activities (5-year summary)Prior1YearDuration_NonConsolidatedMember-1000695000JPY
Net cash provided by used in operating activities (5-year summary)CurrentYearDuration_NonConsolidatedMember-935988000JPY
Net cash provided by used in investing activities (5-year summary)Prior4YearDuration_NonConsolidatedMember-35384000JPY
Net cash provided by used in investing activities (5-year summary)Prior3YearDuration_NonConsolidatedMember－JPY
Net cash provided by used in investing activities (5-year summary)Prior2YearDuration_NonConsolidatedMember173000JPY
Net cash provided by used in investing activities (5-year summary)Prior1YearDuration_NonConsolidatedMember－JPY
Net cash provided by used in investing activities (5-year summary)CurrentYearDuration_NonConsolidatedMember-55463000JPY
Net cash provided by used in financing activities (5-year summary)Prior4YearDuration_NonConsolidatedMember271345000JPY
Net cash provided by used in financing activities (5-year summary)Prior3YearDuration_NonConsolidatedMember1127291000JPY
Net cash provided by used in financing activities (5-year summary)Prior2YearDuration_NonConsolidatedMember667303000JPY
Net cash provided by used in financing activities (5-year summary)Prior1YearDuration_NonConsolidatedMember1738421000JPY
Net cash provided by used in financing activities (5-year summary)CurrentYearDuration_NonConsolidatedMember133198000JPY
Cash and cash equivalents (5-year summary)Prior4YearInstant_NonConsolidatedMember1790988000JPY
Cash and cash equivalents (5-year summary)Prior3YearInstant_NonConsolidatedMember1727270000JPY
Cash and cash equivalents (5-year summary)Prior2YearInstant_NonConsolidatedMember1325554000JPY
Cash and cash equivalents (5-year summary)Prior1YearInstant_NonConsolidatedMember2063280000JPY
Cash and cash equivalents (5-year summary)CurrentYearInstant_NonConsolidatedMember1205026000JPY
Number of employeesPrior4YearInstant_NonConsolidatedMember49
Number of employeesPrior3YearInstant_NonConsolidatedMember49
Number of employeesPrior2YearInstant_NonConsolidatedMember51
Number of employeesPrior1YearInstant_NonConsolidatedMember47
Number of employeesCurrentYearInstant_NonConsolidatedMember49
Average number of temporary workersPrior4YearInstant_NonConsolidatedMember13
Average number of temporary workersPrior3YearInstant_NonConsolidatedMember14
Average number of temporary workersPrior2YearInstant_NonConsolidatedMember17
Average number of temporary workersPrior1YearInstant_NonConsolidatedMember18
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember16
Total shareholder returnPrior4YearInstant_NonConsolidatedMember1.048
Total shareholder returnPrior3YearInstant_NonConsolidatedMember0.957
Total shareholder returnPrior2YearInstant_NonConsolidatedMember0.726
Total shareholder returnPrior1YearInstant_NonConsolidatedMember1.446
Total shareholder returnCurrentYearInstant_NonConsolidatedMember0.575
Total return on share price indexPrior4YearInstant_NonConsolidatedMember0.826
Total return on share price indexPrior3YearInstant_NonConsolidatedMember0.775
Total return on share price indexPrior2YearInstant_NonConsolidatedMember0.745
Total return on share price indexPrior1YearInstant_NonConsolidatedMember0.689
Total return on share price indexCurrentYearInstant_NonConsolidatedMember0.739
Number of employeesCurrentYearInstant_NonConsolidatedMember49
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember16
Average age years information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember45.8
Average length of service years information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember6.3
Average annual salary information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember7676000JPY
Number of employeesCurrentYearInstant_NonConsolidatedMember_ReportableSegmentsMember39
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember_ReportableSegmentsMember15
Number of employeesCurrentYearInstant_NonConsolidatedMember_CorporateSharedMember10
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember_CorporateSharedMember1
Number of employeesCurrentYearInstant_NonConsolidatedMember49
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember16
Capital expenditures overview of capital expenditures etcCurrentYearDuration40080000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember68453800

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2024-12-31pass rounding
balance sheet identitynon_consolidated 2025-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · net assetsnon_consolidated 2025-12-31pass
statement vs summary · operating cash flownon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · operating cash flownon_consolidated 2025-01-01/2025-12-31pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · revenuenon_consolidated 2025-01-01/2025-12-31pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass
statement vs summary · total assetsnon_consolidated 2025-12-31pass